{"product_id":"sibn-vrio-analysis","title":"SI-BONE, Inc. (SIBN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly fuels the competitive edge of SI-BONE, Inc. (SIBN)? This VRIO analysis cuts straight to the core, dissecting the firm's resources based on their Value, Rarity, Inimitability, and Organization to uncover the source of any sustainable advantage. Uncover the strategic truth behind their market position - read the full breakdown below to see if their assets are truly inimitable.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Proprietary Minimally Invasive Surgical (MIS) Implant Systems (iFuse, iFuse-TORQ, Granite)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at SI-BONE’s core technology - the MIS implants - as the engine for future growth. The data from 2025 shows this engine is running hot, with strong procedure demand driving revenue up toward \u003cstrong\u003e$200 million\u003c\/strong\u003e for the year. This isn't just about selling hardware; it’s about owning the minimally invasive sacroiliac joint (SI joint) procedure space.\u003c\/p\u003e\n\n\u003ch\u003eValue: Less Invasive Treatment Driving Adoption\u003c\/h\u003e\n\u003cp\u003eThe value proposition here is clear: less invasive surgery means better patient experiences and faster surgeon buy-in compared to traditional open procedures. We see this reflected in the numbers. As of Q2 2025, SI-BONE had 1,440 active U.S. physicians, a growth of about 25% year-over-year, showing surgeons are adopting the platform quickly. Furthermore, the company is guiding for full-year 2025 worldwide revenue between $198 million and $200 million, which is growth of 18% to 20% over 2024. That growth is the market voting for the value of MIS.\u003c\/p\u003e\n\u003cp\u003eThe financial structure also supports the value of adoption:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ2 2025 U.S. revenue hit \u003cstrong\u003e$46.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTrailing 12-month average revenue per territory grew ~\u003cstrong\u003e23%\u003c\/strong\u003e to \u003cstrong\u003e$2.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe reimbursement tailwinds are cementing this value.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Specialized Design and Application\u003c\/h\u003e\n\u003cp\u003eHonestly, the specific engineering and procedural know-how for the iFuse, iFuse-TORQ, and Granite systems in MIS SI joint fusion is rare. While other companies offer SI joint solutions, SI-BONE’s lateral approach portfolio is highly specialized. Competitors simply don't have the same depth of patented titanium implant designs tailored specifically for this niche, which is why they are the market leader in this segment.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Complexity and Clinical Trust as Barriers\u003c\/h\u003e\n\u003cp\u003eImitating this isn't just about copying a blueprint; it’s about replicating years of clinical validation. The complexity of the implant design - especially the porous structure of iFuse-3D or the screw mechanics of iFuse-TORQ - is hard to copy quickly. More importantly, surgeon trust is built on clinical evidence, not marketing copy. Gaining the trust needed to displace an established system takes significant time and successful patient outcomes, making direct imitation a high hurdle.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Platform Expansion and Reimbursement Focus\u003c\/h\u003e\n\u003cp\u003eSI-BONE is organized to capitalize on this technology. Their focus on platform expansion, evidenced by the successful launch of iFuse-TORQ across Europe in 2025, shows international execution is in place. Organizationally, securing favorable reimbursement is key, and they achieved major milestones in 2025. The Centers for Medicare and Medicaid Services (CMS) confirmed the New Technology Add-On Payment (NTAP) for iFuse TORQ TNT procedures starting October 1, 2025, potentially adding up to \u003cstrong\u003e$4,136\u003c\/strong\u003e per case. Plus, Granite secured Transitional Pass-Through (TPT) payment status effective January 1, 2025, for outpatient use. They are defintely set up to convert procedure growth into revenue.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained Market Leadership\u003c\/h\u003e\n\u003cp\u003eThe combination of proprietary tech, high barriers to imitation, and strong organizational support for adoption and reimbursement points to a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. They are the established leader, and their focus on new product rollouts and securing payment pathways means new entrants face an uphill battle against an entrenched, clinically validated platform.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick summary of how the MIS Implant Systems score:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003e2025 Supporting Data\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e2025 Revenue Guidance: \u003cstrong\u003e$198M - $200M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eProprietary MIS design for SI joint fusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eHigh complexity and established clinical evidence base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eiFuse-TORQ launched in Europe; Granite TPT active in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eStrong procedural adoption with ~\u003cstrong\u003e22%\u003c\/strong\u003e Q3 procedure volume growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Extensive, Clinically Validated Evidence Base\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Over \u003cstrong\u003e175\u003c\/strong\u003e peer-reviewed publications, including two randomized controlled trials, directly support the efficacy and safety of their technology, which is crucial for physician buy-in and reimbursement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare for a company of this size to have such a deep, high-quality body of clinical literature specific to their niche. As of Q3 2025, the evidence base includes over \u003cstrong\u003e180\u003c\/strong\u003e peer-reviewed publications and \u003cstrong\u003efour\u003c\/strong\u003e randomized controlled trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; replicating this level of clinical proof takes years of costly, successful trials. The company has supported over \u003cstrong\u003e4,900\u003c\/strong\u003e physicians in performing a total of over \u003cstrong\u003e135,000\u003c\/strong\u003e procedures since pioneering minimally invasive SI joint surgery in 2009.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective; management explicitly references this evidence as a driver for physician adoption and commercial success. Full year 2025 worldwide revenue guidance is in the range of \u003cstrong\u003e$198 million to $200 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this evidence builds trust that new competitors cannot quickly overcome. The gross margin for Q3 2025 was \u003cstrong\u003e79.8%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey metrics supporting the evidence base:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eReporting Period\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Procedures Performed\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e135,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreating Physicians Supported\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e4,900\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer-Reviewed Publications\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e180\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRandomized Controlled Trials (RCTs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFour\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Gross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe clinical validation includes specific study types:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTwo randomized controlled trials (RCTs) in the US and Europe comparing iFuse vs. Non-surgical Management.\u003c\/li\u003e\n\u003cli\u003eLong-Term Prospective Trial with \u003cstrong\u003e5-year\u003c\/strong\u003e Results reported for iFuse 3D.\u003c\/li\u003e\n\u003cli\u003ePublication of \u003cstrong\u003e5-year\u003c\/strong\u003e results from a subset of patients in the LOIS study, which included participants from the INSITE (U.S. RCT) and SIFI prospective multicenter trial.\u003c\/li\u003e\n\u003cli\u003eDemonstrated pain reduction of \u003cstrong\u003e54 points\u003c\/strong\u003e from baseline (0–100 scale) at \u003cstrong\u003e5 years\u003c\/strong\u003e post-surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Established Surgeon Training and Procedural Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The company has supported over \u003cstrong\u003e4,600\u003c\/strong\u003e physicians performing a total of nearly \u003cstrong\u003e130,000\u003c\/strong\u003e procedures since pioneering minimally invasive SI joint surgery in 2009, creating a large, trained user base familiar with the SI-BONE technique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the depth of experience specifically in MIS SI joint fusion is concentrated here, supported by a unique body of clinical evidence.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate to High; imitation requires replicating the entire educational infrastructure and time-in-field experience.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; recent data shows continued physician base expansion.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary to Sustained; sustained as long as they keep growing the trained base faster than competitors can catch up, relative to the total addressable market.\u003c\/p\u003e\n\u003cp\u003eKey Metrics Supporting Procedural Expertise:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Latest Cumulative\/Period End)\u003c\/td\u003e\n\u003ctd\u003ePeriod End Date\u003c\/td\u003e\n\u003ctd\u003eCitation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Procedures Performed (Cumulative)\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e130,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Physicians Supported (Cumulative)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e4,600\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Active Physicians\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e1,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Physicians Performing Procedures (Annual)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e2,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer Reviewed Publications\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e175\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRandomized Controlled Trials (RCTs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFour\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Addressable Market (Procedures)\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e500,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024\/2025\u003c\/td\u003e\n\u003ctd\u003e5, 7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePhysician Base Growth:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. Active Physicians in Q3 2024: Over \u003cstrong\u003e1,200\u003c\/strong\u003e, representing an increase of \u003cstrong\u003e~15%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eU.S. Physicians Performing Procedures in 2024: More than \u003cstrong\u003e2,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eU.S. Physicians Performing Procedures in 2023: Over \u003cstrong\u003e1,600\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eClinical Evidence Depth:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNumber of Peer Reviewed Publications: \u003cstrong\u003eOver 175\u003c\/strong\u003e as of Q2 2025.\u003c\/li\u003e\n\u003cli\u003eNumber of Randomized Controlled Trials: \u003cstrong\u003eFour\u003c\/strong\u003e as of Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Patented Titanium Implant Technology and IP Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects the core product designs, like the fenestrated design of iFuse-3D, with U.S. patents extending to \u003cstrong\u003eSeptember 2035\u003c\/strong\u003e, securing future revenue streams.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; other companies have patents, but the specific, foundational patents for MIS SI joint fusion are unique to SI-BONE, Inc.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; direct imitation is blocked by the patent life, though competitors can design around them.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Organized to defend; they actively manage their portfolio, with \u003cstrong\u003e68\u003c\/strong\u003e U.S. patents issued and \u003cstrong\u003e40\u003c\/strong\u003e pending as of \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (for now); the long patent runway provides a clear moat against direct product copying.\u003c\/p\u003e\n\u003cp\u003eKey Patent Expiration Dates:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\/Technology\u003c\/td\u003e\n\u003ctd\u003eU.S. Patent Expiration Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eiFuse-3D Implant (Fenestrated Design)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 2035\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiFuse Bedrock Granite Implants\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 2039\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTriangular Cutting Tool\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 2034\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Generation iFuse Implant (Triangular Shape)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupporting Statistical Data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe iFuse Implant System has been used in over \u003cstrong\u003e26,000\u003c\/strong\u003e procedures since \u003cstrong\u003e2009\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe iFuse-3D Implant provides \u003cstrong\u003e250%\u003c\/strong\u003e greater porous surface area than the original iFuse implant.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eFebruary 20, 2025\u003c\/strong\u003e, the number of shares of Registrant's Common Stock outstanding was \u003cstrong\u003e42,453,116\u003c\/strong\u003e shares.\u003c\/li\u003e\n\u003cli\u003eThe SI joint has been attributed as a source of pain in \u003cstrong\u003e15-30 percent\u003c\/strong\u003e of patients with chronic low back pain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: High Gross Margin Profile\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A forecasted full-year 2025 gross margin of \u003cstrong\u003e79.5%\u003c\/strong\u003e provides significant operating leverage as revenue grows, directly fueling profitability goals like positive adjusted EBITDA. Q2 2025 adjusted EBITDA was \u003cstrong\u003e$1.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; high margins are common in med-tech, but this level, combined with their growth, is notable. Q2 2025 gross margin was \u003cstrong\u003e79.8%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can achieve similar margins, but only after matching the scale and efficiency of their current production.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Highly effective; they improved gross margin to \u003cstrong\u003e79.8%\u003c\/strong\u003e in Q2 2025, showing operational control. Q3 2025 gross margin was also \u003cstrong\u003e79.8%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it's a result of scale and process, which can be matched over time.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecasted Full-Year Gross Margin\u003c\/td\u003e\n\u003ctd\u003e2025 (Latest Guidance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e79%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ4 2023\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e74%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Months Revenue\u003c\/td\u003e\n\u003ctd\u003eAs of Latest Report\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$185.26 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational highlights supporting margin include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eActive U.S. physicians reached \u003cstrong\u003e1,440\u003c\/strong\u003e in Q2 2025, representing growth of \u003cstrong\u003e25%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eTrailing 12-month average revenue per territory reached \u003cstrong\u003e$2.1 million\u003c\/strong\u003e in Q2 2025, an increase of \u003cstrong\u003e~23%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNew Technology Add-on Payment (“NTAP”) of over \u003cstrong\u003e$4,100\u003c\/strong\u003e for iFuse TORQ TNT procedures effective October 1, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Market Leadership in a Niche Indication (SI Joint Dysfunction)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Being the pioneer means they often define the standard of care, capture initial market share, and benefit from procedure awareness campaigns.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe iFuse Implant System was FDA cleared in \u003cstrong\u003e2009\u003c\/strong\u003e. Clinical studies indicate that the sacroiliac joint is associated with 15% to 30% of all chronic lower back pain. The global sacroiliac joint fusion market was estimated at USD 721.2 million in 2023.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Procedures Performed (Cumulative)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e135,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025 (cumulative since 2009)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Procedures Performed\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e15,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFY 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive U.S. Physicians\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,440\u003c\/strong\u003e (growth of \u003cstrong\u003e~25%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorldwide Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$48.6 million\u003c\/strong\u003e (growth of \u003cstrong\u003e21.7%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: High; they essentially created and dominate the MIS segment for this specific joint disorder.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe iFuse Implant is the only device for SI joint dysfunction treatment supported by significant published clinical evidence, including two Level I Randomized Controlled Trials. As of Q4 2023, over 1,600 U.S. physicians performed procedures.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High; establishing a category takes significant time and investment in education and awareness.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company has supported over 4,900 physicians since pioneering minimally invasive SI joint surgery in 2009. The iFuse device has led the market for several years.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Excellent; they are leveraging this leadership to expand into adjacent markets like adult deformity.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSI-BONE leverages its leadership to commercialize novel solutions for adjacent markets, including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eAdult deformity\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSacropelvic fixation\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePelvic trauma\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company received 510(k) clearance for the smaller diameter iFuse Bedrock Granite implant with S1 and pediatric deformity indication in Q4 2023. CMS confirmed a New Technology Add-On Payment (“NTAP”) up to $4,136 for iFuse TORQ TNT procedures, effective October 1, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; category creation is a powerful, long-lasting advantage.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company projects 2025 worldwide revenue between $195 million to $198 million, implying year-over-year growth of ~17% to ~18%. The Gross Margin for FY 2023 was ~79%, and the Q2 2025 Gross Margin was 79.8%.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Growing Territory Productivity and Sales Execution\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eTrailing 12-month average revenue per territory was \u003cstrong\u003e$2.1 million\u003c\/strong\u003e as of Q2 2025, showing an increase of \u003cstrong\u003e~23%\u003c\/strong\u003e year-over-year, indicating highly efficient sales execution. This productivity metric is supported by a growing physician base, with \u003cstrong\u003e1,440\u003c\/strong\u003e active U.S. physicians as of Q2 2025, a growth of \u003cstrong\u003e~25%\u003c\/strong\u003e year-over-year. The company reported double-digit procedure volume growth across all U.S. target markets in Q2 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Average Revenue per Territory\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Revenue per Territory YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive U.S. Physicians\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,440\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive U.S. Physician Growth YoY\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious TTM Productivity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; high territory productivity, evidenced by the \u003cstrong\u003e$2.1 million\u003c\/strong\u003e TTM average, signals a strong product-market fit and effective sales training. The consistent growth, such as the \u003cstrong\u003e27.3%\u003c\/strong\u003e growth in active U.S. physicians in Q1 2025, further supports this.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eModerate; requires replicating their specific sales training, compensation structure, and physician targeting strategy, which drove the TTM revenue per territory up by \u003cstrong\u003e~23%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eStrong; this metric shows the sales organization is well-aligned with the clinical value proposition, as demonstrated by operational achievements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. revenue growth of \u003cstrong\u003e22.8%\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eAchieved positive Adjusted EBITDA of \u003cstrong\u003e$1.0 million\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eNet cash generated of \u003cstrong\u003e$1.1 million\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eFull year 2024 worldwide revenue growth of approximately \u003cstrong\u003e20%\u003c\/strong\u003e to between \u003cstrong\u003e$167.0 million\u003c\/strong\u003e and \u003cstrong\u003e$167.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; high productivity, such as the \u003cstrong\u003e~23%\u003c\/strong\u003e year-over-year increase in territory revenue, can erode if new competitors enter with compelling alternatives to the iFuse Technology\u003csup\u003e®\u003c\/sup\u003e platform.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Positive Trajectory in Profitability and Cash Flow Inflection\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eAchieving positive adjusted EBITDA ($2.3 million in Q3 2025) and reaching positive cash flow from operating activities for two consecutive quarters signals financial stability and a path to self-funding growth.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow from Operations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.1 million\u003c\/strong\u003e generated\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.3 million\u003c\/strong\u003e generated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; many growth-stage med-tech firms struggle to cross this profitability threshold. The Q3 2025 Adjusted EBITDA margin was approximately 5% on $48.7 million in worldwide revenue.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow; this is an internal achievement based on operational discipline and revenue scale, not an external asset. The U.S. active physician base grew 27% year-over-year to 1,530 in Q3 2025.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHighly effective; management is clearly focused on operational leverage, which is paying off. Key Q3 2025 financial results supporting this include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorldwide revenue growth of 20.6% to $48.7 million.\u003c\/li\u003e\n\u003cli\u003eGross margin of 79.8%.\u003c\/li\u003e\n\u003cli\u003eOperating expenses increased 11.9% to $44.2 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; once a company achieves this inflection point, it changes the competitive dynamic in its favor. The company ended Q3 2025 with $145.7 million in cash and equivalents.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSI-BONE, Inc. (SIBN) - VRIO Analysis: Platform Expansion into Adjacent Spine Markets\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLeveraging core competencies to commercialize novel solutions for adult deformity, spinopelvic fixation, and pelvic trauma diversifies revenue risk away from the core SI joint indication. The iFuse TORQ TNT™ Implant System, cleared via 510(k), addresses pelvic fragility fracture fixation, a market where up to \u003cstrong\u003e85%\u003c\/strong\u003e of SI trauma patients develop ongoing pain or poor function due to malreduction.\u003csup\u003e13\u003c\/sup\u003e The iFuse Bedrock Granite System is used as a foundational element for multi-segment spinal fusion, addressing high failure rates in Adult Spinal Deformity (ASD) fixation, where lumbosacral and pelvic fixation failure rates were reported at \u003cstrong\u003e24%\u003c\/strong\u003e within a 2-year follow-up.\u003csup\u003e10\u003c\/sup\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate; many specialized firms fail to successfully cross-sell or expand into new, related surgical areas. SI-BONE, Inc. has demonstrated success in adjacent markets, with \u003cstrong\u003e1,530\u003c\/strong\u003e active U.S. physicians as of Q3 2025, a \u003cstrong\u003e27%\u003c\/strong\u003e year-over-year growth.\u003csup\u003e2\u003c\/sup\u003e International Revenue in Q3 2025 was \u003cstrong\u003e$2.3 million\u003c\/strong\u003e.\u003csup\u003e1\u003c\/sup\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate; it requires the same R\u0026amp;D and regulatory skill set, which SI-BONE, Inc. has demonstrated. The company received FDA 510(k) clearance and Breakthrough Device Designation (BDD) for the iFuse TORQ TNT™ Implant System.\u003csup\u003e7, 8\u003c\/sup\u003e The company's Q3 2025 Gross Margin was \u003cstrong\u003e79.8%\u003c\/strong\u003e.\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nProactive; they are filing 510(k)s for next-generation tech expected in early 2026, showing a forward-looking pipeline. The company raised its Full Year 2025 worldwide revenue guidance to range between \u003cstrong\u003e$198 million\u003c\/strong\u003e to \u003cstrong\u003e$200 million\u003c\/strong\u003e.\u003csup\u003e4\u003c\/sup\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary; sustained only if the expansion products gain significant traction against established players in those markets. The company achieved a positive Adjusted EBITDA of \u003cstrong\u003e$2.3 million\u003c\/strong\u003e in Q3 2025, representing an adjusted EBITDA margin of approximately \u003cstrong\u003e5%\u003c\/strong\u003e.\u003csup\u003e4\u003c\/sup\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\nFinancial Data and 13-Week Cash Flow Projection Context:\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (Starting Point for Projection)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorldwide Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$46.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$145.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nSupporting Operational Metrics:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrailing 12-month average revenue per territory increased by \u003cstrong\u003e16%\u003c\/strong\u003e.\u003csup\u003e3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eNew Technology Add-on Payment (NTAP) for iFuse TORQ TNT procedures is over \u003cstrong\u003e$4,100\u003c\/strong\u003e effective October 1, 2025.\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company reported an operating loss improvement of \u003cstrong\u003e29.5%\u003c\/strong\u003e to \u003cstrong\u003e$5.4 million\u003c\/strong\u003e in Q3 2025.\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eOperating expenses increased by \u003cstrong\u003e11.9%\u003c\/strong\u003e to \u003cstrong\u003e$44.2 million\u003c\/strong\u003e in Q3 2025.\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516250284181,"sku":"sibn-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sibn-vrio-analysis.png?v=1740214838","url":"https:\/\/dcf-model.com\/products\/sibn-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}